TRV
56
-2
ROK
67
5
MPC
47
3
BMY
61
-3
RSG
77
4
XEL
65
-2
XOM
51
3
HPE
70
2
JCI
61
-2
DVA
72
-3
PX
73
-6
HRL
30
-3
AAPL
45
3
DOW
30
2
GS
75
-4
KO
44
2
PG
50
2
RRC
60
-3
NOC
40
-10
AVGO
35
-2
TRV
56
-2
ROK
67
5
MPC
47
3
BMY
61
-3
RSG
77
4
XEL
65
-2
XOM
51
3
HPE
70
2
JCI
61
-2
DVA
72
-3
PX
73
-6
HRL
30
-3
AAPL
45
3
DOW
30
2
GS
75
-4
KO
44
2
PG
50
2
RRC
60
-3
NOC
40
-10
AVGO
35
-2
Financhill
Back

Cidara Therapeutics 10K Form

Buy
62

CDTX
Cidara Therapeutics

Last Price:
14.66
Seasonality Move:
7.85%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDTX News And Ratings

See the #1 stock for the next 7 days that we like better than CDTX

CDTX Financial Statistics

Sales & Book Value

Annual Sales: $63.91M
Cash Flow: $-103.78M
Price / Cash Flow: 0
Annual Sales: $28.66
Price / Book: 0.72

Profitability

EPS (TTM): -25.27000
Net Income (TTM): $-115.32M
Gross Margin: $62.38M
Return on Equity: -449.07%
Return on Assets: -135.81%

Cidara Therapeutics Earnings Forecast

Key Cidara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CDTX is 97.62%.
  • The Selling, General & Administrative Expenses for CDTX have been equal to 28.69% of Gross Profit Margin.
  • The Research & Development expenses have been 107.24% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Cidara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDTX
CUSIP: 171757
Website: cidara.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.25
Quick Ratio: 4.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CDTX Technical Analysis vs Fundamental Analysis

Buy
62
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics a Buy or a Sell?